By contrast, Claudel andcolleagues demonstrated that treatment with the dual PPARα/γ compound,GW2331, for 11 weeks was more effective at attenuating atherosclerosis infemale apoE KO mice than rosiglitazone alone [105]. Here, PPARA is linked to atherosclerosis.